Canada markets closed

Generation Bio Co. (GBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.0700-0.0600 (-1.92%)
At close: 04:00PM EDT
3.0100 -0.06 (-1.95%)
After hours: 07:21PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.1300
Open3.1600
Bid3.0400 x 200
Ask3.1000 x 200
Day's Range3.0300 - 3.2700
52 Week Range0.8600 - 6.9800
Volume75,923
Avg. Volume234,358
Market Cap204.243M
Beta (5Y Monthly)2.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results

    - Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP) - ASGCT poster presentations described immune-quiet DNA (iqDNA) as partially single-stranded, produced by flexible, scalable, proprietary rapid enzymatic synthesis - Cash balance of $233.9 million still expected to fund operations into 2H 2027 CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechno

  • GlobeNewswire

    Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting

    Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensorsRapid enzymatic synthesis continues to improve iqDNA performance through process development and the identification of novel structural elements Data on cell-targeted LNP (ctLNP) in vivo delivery of therapeutic transgenes to T cells to be discussed in an oral presentation on Saturday, May 11 CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Generatio

  • GlobeNewswire

    Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

    CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six abstracts highlighting preclinical data from its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms have been accepted for presentation, including one oral presentation, at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking p